<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1207</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2019-47-081</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Is there a place for multivisceral resections in the treatment of gastric cancer?</article-title><trans-title-group xml:lang="ru"><trans-title>Есть ли место мультивисцеральным резекциям в лечении рака желудка?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Смирнов</surname><given-names>А. B.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Alexander V. Smirnov – </bold>MD, PhD, Associate Professor, Chair of Surgery</p><p><italic>28 Orekhovyy bul'var, Moscow, 115682, Russian Federation</italic></p></bio><bio xml:lang="ru"><p><bold>Смирнов Александр Вячеславович – </bold>канд. мед. наук, доцент кафедры хирургии</p><p><italic>115682, г. Москва, Ореховый бульвар, 28</italic></p></bio><email>alvsmirnov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cherepanin</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Черепанин</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Andrey I. Cherepanin – </bold>MD, PhD, Professor, Head of the Chair of Surgery</p><p><italic>91 Volokolamskoe shosse, Moscow, 125371, Russian Federation</italic></p></bio><bio xml:lang="ru"><p><bold>Черепанин Андрей Игоревич – </bold>д-р мед. наук, профессор, заведующий кафедрой хирургии</p><p><italic>125371, г. Москва, Волоколамское шоссе, 91</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ishchenko</surname><given-names>R. V.</given-names></name><name xml:lang="ru"><surname>Ищенко</surname><given-names>Р. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Roman V. Ishchenko – </bold>MD, PhD, Professor, Chair of Surgery</p><p><italic>91 Volokolamskoe shosse, Moscow, 125371, Russian Federation</italic></p></bio><bio xml:lang="ru"><p><bold>Ищенко Роман Викторович – </bold>д-р мед. наук, профессор кафедры хирургии</p><p><italic>125371, г. Москва, Волоколамское шоссе, 91</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Postgraduate Academy of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies</institution></aff><aff><institution xml:lang="ru">Академия постдипломного образования ФГБУ ФНКЦ ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-01-01" publication-format="electronic"><day>01</day><month>01</month><year>2020</year></pub-date><volume>47</volume><issue>8</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>707</fpage><lpage>711</lpage><history><date date-type="received" iso-8601-date="2019-12-31"><day>31</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Smirnov A.V., Cherepanin A.I., Ishchenko R.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Смирнов А.B., Черепанин А.И., Ищенко Р.В.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Smirnov A.V., Cherepanin A.I., Ishchenko R.V.</copyright-holder><copyright-holder xml:lang="ru">Смирнов А.B., Черепанин А.И., Ищенко Р.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/1207">https://almclinmed.ru/jour/article/view/1207</self-uri><abstract xml:lang="en"><p>It is known that multivisceral resections (MVR) are associated with significant numbers of post-operative complications. However, the effectiveness of MVR in increasing the patients' life expectancy remains a matter of debate. Are the risks of extended volume resections justified? It has been previously assumed that the removal of adjacent organs could improve the prognosis of the disease, even in the absence of direct invasion. However, in the era of the big potential of chemoand radiation therapy, the implementation of an over-extensive surgical volume in the absence of tumor invasion is doubtful. In the presence of regional lymphatic nodes metastases, MVR do not improve prognosis, compared to that after palliative resections. If the patient has distant metastases, or the operation has been obviously not radical enough, MVR worsen the prognosis. In grade T4b invasion and with the absence of life threatening complications, it is optimal to start with neoadjuvant or perioperative chemotherapy. In the case of intraoperative suspicion of adjacent anatomical structures involvement, with no distant metastases, en bloc resection in combination with D2 lymphodissection is indicated. In approximately 30–60% of cases, invasion is not confirmed by histology. The only way to improve the results of surgical treatment of gastric cancer patients is to carefully assess the extension of the disease at the preoperative stage, select patients and team work of surgeons with chemotherapists, radiologists and specialists in diagnostics.</p></abstract><trans-abstract xml:lang="ru"><p>Общеизвестно, что мультивисцеральные резекции (МВР) сопровождаются значительным числом послеоперационных осложнений. Однако до сих пор идут дискуссии об эффективности МВР в отношении увеличения продолжительности жизни больных. Оправданы ли риски операций расширенного объема? Ранее предполагалось, что удаление соседних органов может улучшить прогноз заболевания, даже в отсутствие прямой инвазии. Но в эпоху широких возможностей химио- и лучевой терапии выполнение сверхрасширенного хирургического объема без прорастания опухоли вызывает сомнения. При наличии метастазов в регионарные лимфоузлы МВР не улучшают прогноз в сравнении с паллиативными резекциями. В случае если у пациента есть отдаленные метастазы либо операция проведена заведомо нерадикально, МВР ухудшают прогноз. Если степень инвазии T4b и нет жизнеугрожающих осложнений, оптимально начать неоадъювантную химиотерапию или провести периоперационную химиотерапию. При интраоперационном подозрении на вовлечение соседних анатомических структур в отсутствие отдаленных метастазов показана резекция en bloc в сочетании с D2-лимфодиссекцией. Приблизительно в 30–60% наблюдений инвазия морфологически не подтверждается. Единственный путь улучшения результатов хирургического лечения больных раком желудка – тщательная оценка распространенности заболевания на дооперационном этапе, отбор больных и работа хирургов в команде с химиотерапевтами, радиологами и диагностами.</p></trans-abstract><kwd-group xml:lang="en"><kwd>gastric cancer</kwd><kwd>multivisceral resection</kwd><kwd>lymphodissection</kwd><kwd>abdominal evisceration</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак желудка</kwd><kwd>мультивисцеральная резекция</kwd><kwd>лимфодиссекция</kwd><kwd>абдоминальная эвисцерация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Каприн АД, Старинский ВВ, Петрова ГВ, ред. Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	NCCN Guidelines Version 2.2019 Gastric Cancer [Internet]. 03.06.2019. URL: https://www.nccn.org/professionals/physician_gls/pdf/ gastric.pdf (Accessed: 05.11.2019).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Furukawa H, Hiratsuka M, Iwanaga T. A rational technique for surgical operation on Borrmann type 4 gastric carcinoma: left upper abdominal evisceration plus Appleby's method. Br J Surg. 1988;75(2):116–9. doi: 10.1002/bjs.1800750209.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, Sasaki Y, Kameyama M, Ohigashi H, Nakamori S, Yasuda T. Extended surgery – left upper abdominal exenteration plus Appleby's method – for type 4 gastric carcinoma. Ann Surg Oncol. 1997;4(3):209–14. doi: 10.1007/bf02306612.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Isozaki H, Tanaka N, Fujii K, Tanigawa N, Okajima K. Improvement of the prognosis of gastric cancer with extensive serosal invasion using left upper abdominal evisceration. Hepatogastroenterology. 2001;48(40):1179–82.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Yonemura Y, Kawamura T, Nojima N, Bandou E, Keizou T, Fujita H, Michiwa Y, Fujimura T, Fushida S, Ajisaka H, Miwa K. Postoperative results of left upper abdominal evisceration for advanced gastric cancer. Hepatogastroenterology. 2000;47(32):571–4.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. doi: 10.1007/s10120-016-0622-4.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Jiang L, Yang KH, Chen Y, Guan QL, Zhao P, Tian JH, Wang Q. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Surg. 2014;101(6):595–604. doi: 10.1002/bjs.9497.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg. 2002;195(6): 855–64. doi: 10.1016/s1072-7515(02)01496-5.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22(3):1139–59. doi: 10.3748/wjg.v22.i3.1139.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Brar SS, Seevaratnam R, Cardoso R, Yohanathan L, Law C, Helyer L, Coburn NG. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer. 2012;15 Suppl 1:S100– 7. doi: 10.1007/s10120-011-0074-9.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Dhar DK, Kubota H, Tachibana M, Kinugasa S, Masunaga R, Shibakita M, Kohno H, Nagasue N. Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol. 2001;76(4):278–82. doi: 10.1002/jso.1046.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg. 2002;236(2):159–65. doi: 10.1097/00000658200208000-00003.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I, Carlini M, Santoro E. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol. 2005;90(2):95–100. doi: 10.1002/jso.20244.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, Kece C, Atalay F, Akoglu M. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009;198(1):25–30. doi: 10.1016/j.amjsurg.2008.06.031.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol. 2009;100(2):115–20. doi: 10.1002/jso.21306.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.	Cheng CT, Tsai CY, Hsu JT, Vinayak R, Liu KH, Yeh CN, Yeh TS, Hwang TL, Jan YY. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18(6):1606–14. doi: 10.1245/s10434-0101534-x.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.	Coimbra FJ, da Costa WL Jr, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, Filho AM, Fanelli MF, Begnami MD, Soares FA. Noncurative resection for gastric cancer patients: who could benefit? : Determining prognostic factors for patient selection. Ann Surg Oncol. 2016;23(4):1212–9. doi: 10.1245/s10434-015-4945-x.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.	Lowenfeld L, Datta J, Lewis RS Jr, McMillan MT, Mamtani R, Damjanov N, Chandrasekhara V, Karakousis GC, Drebin JA, Fraker DL, Roses RE. Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Ann Surg Oncol. 2015;22 Suppl 3:S863–72. doi: 10.1245/s10434-015-4677-y.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.	Ревтович МЮ, Суконко ОГ, Шмак АИ, Красько ОВ. Комбинированные операции у пациентов с резектабельным раком желудка. Весці Нацыянальнай акадэміі навук Беларусі. Серыя медыцынскіх навук. 2018;15(2): 207–14. doi: 10.29235/1814-6023-2018-152-207-214.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.	Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002;80(4):181–5. doi: 10.1002/jso.10127.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.	Филатов АА, Будурова МД, Герасимов СС, Давыдов ММ. Хирургическое лечение больных раком желудка, осложненным кровотечением. Вестник «РОНЦ им. Н.Н. Блохина РАМН». 2016;27(3):5–14.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.	Давыдов ММ, Будурова МД, Шогенов МС, Глухов ЕВ, Чекини АК, Филатов АА. Результаты хирургического лечения больных раком желудка, осложненным перфорацией. Вестник «РОНЦ им. Н.Н. Блохина РАМН». 2018;29(4):8–15.</mixed-citation></ref></ref-list></back></article>
